about
A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell linesEvaluation of quinacrine treatment for prion diseasesAntihypertensive drug guanabenz is active in vivo against both yeast and mammalian prionsThe efficacy of tetracyclines in peripheral and intracerebral prion infection.From high-throughput cell culture screening to mouse model: identification of new inhibitor classes against prion disease.New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products.Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity.Role of plasminogen in propagation of scrapie.Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseasesReduction of PrP(C) in human cerebrospinal fluid after spinal cord injury.Successes and challenges in phenotype-based lead discovery for prion diseasesMefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivoA porphyrin increases survival time of mice after intracerebral prion infectionProtein quality control in heart disease: using established drugs to target novel mechanisms.Computational approaches to shed light on molecular mechanisms in biological processesProteomic consequences of expression and pathological conversion of the prion protein in inducible neuroblastoma N2a cells.Therapeutic approaches in treating Creutzfeldt-Jakob disease - what does the future hold?Recent advances in prion chemotherapeutics.An overview of transmissible spongiform encephalopathies.The prion protein: Structural features and related toxic peptides.Assessment of prospective preventive therapies for chronic wasting disease in mule deerTherapeutic approaches for prion disorders.Pharmacological chaperone reshapes the energy landscape for folding and aggregation of the prion proteinApplication of an in vitro-amplification assay as a novel pre-screening test for compounds inhibiting the aggregation of prion protein scrapiePrions: Beyond a Single Protein.Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfoldingThe role of the unusual threonine string in the conversion of prion protein.Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature.Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action.Inhibition of aggregate formation as therapeutic target in protein misfolding diseases: effect of tetracycline and trehalose.Modulation of prion protein oligomerization, aggregation, and beta-sheet conversion by 4,4'-dianilino-1,1'-binaphthyl-5,5'-sulfonate (bis-ANS).Approaches for discovering anti-prion compounds: lessons learned and challenges ahead.An antipsychotic drug exerts anti-prion effects by altering the localization of the cellular prion protein.Treatment with a non-toxic, self-replicating anti-prion delays or prevents prion disease in vivo.Rational approach to an antiprion compound with a multiple mechanism of action.Insights from Therapeutic Studies for PrP Prion Disease.Combined Creutzfeldt-Jakob-Jacob/ Alzheimer's Disease Cases are Important in Search for Microbes in Alzheimer's Disease.Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease.Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner.Doxycycline attenuates protein aggregation in cardiomyocytes and improves survival of a mouse model of cardiac proteinopathy.
P2860
Q21562652-DBAEA3FD-576C-4C0A-A1EA-768936E96FBCQ24682427-168A69A8-7617-48F1-A8D3-2E55CCB74079Q28472560-EDB15A51-190D-4FDA-BE27-0E177665CDE3Q30496598-650A0583-DCB7-41DA-885F-ACB5356DCE7AQ31023317-248C0620-2FFC-4A28-B30B-33B4BFF9DDCAQ31156724-1A70B720-C733-4FFE-865D-9779A77A94F1Q33560026-16A0719F-CD7C-4B70-90EC-B96425688534Q33930530-A44B417F-AAB0-4C00-AEF7-CDE9C2397C7DQ34044084-1F6643AF-6CEA-45B1-98FE-F73190C07C5FQ34102648-6B05A73E-691E-48EC-AE3A-92F3E3459C3BQ34104276-2A063D3B-DE7F-4C8E-A331-110968358010Q34301832-EF9451CE-DA56-4DFD-B509-0117ABDA2CFBQ34352240-92AEF830-CDCB-44E2-9759-F131B78F9192Q34369511-7BB3F2CD-F6D9-4DFF-BF91-2AB97C35B798Q34671563-4F79EAA5-1D7A-4264-ADAD-8AF2892BC5D6Q35714147-22A5EAAB-B80F-4D69-B60A-174DD72DBB20Q35925559-0D72E558-5C77-4639-AA82-22DC9751A67CQ35944199-C3BF72E7-23CD-4444-8360-157C2104C053Q36177322-8ED95E89-F322-4817-B75C-F1CA22B2687DQ36633451-CA1B29C1-3025-49DB-B683-0AB27D049ECBQ36659214-5D504D2A-6425-400E-8626-B45AEAB2D9CEQ36901944-7B5E9FC8-1111-4F82-9A48-513D6080D09BQ37060996-368C92F2-913F-49DA-A7D3-9D947787FCBDQ37072897-61306516-098F-4C51-B041-FDD96E595044Q37162363-472293A2-8307-46E0-87E0-52C8748C8675Q37490746-B8B20ECA-B9EC-4808-8C9E-F8C457A32491Q37508301-4555C98A-7213-4AEC-8F4A-112FCA26EA29Q37769021-5E34CBE0-F92B-467A-A510-F11D835FB048Q37800572-FFD9FD71-00C6-4D89-A1D8-2162EA3CCBFDQ37807985-F870661E-48C6-4E9E-BDF3-5653D60D5917Q38347673-B8533AAC-8672-445F-B576-AB7AEF389005Q38356026-0F206DA5-B423-462C-99C1-272D96572C52Q38634933-E2196E88-A762-443C-A507-771A9DACB94EQ38718288-14DA79D7-BE47-49F7-942B-8C6B02D08711Q38948910-2DB4D378-04D9-4351-B1DB-8F8ED359A1BCQ39005891-96288E49-5E3D-4BDA-AC9C-EB2E8F27E165Q39036381-69523E83-E3F9-4EC5-97F2-4DE5AA5CC58AQ39458294-0862067F-56B9-4690-9DCD-F93AA43AA9F3Q40078261-FDC91D77-3FAF-4AAB-AAB4-EB33F8A12E7FQ41791468-4517D662-71FE-4E0F-AA68-59917650743B
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Tetracyclines affect prion infectivity.
@ast
Tetracyclines affect prion infectivity.
@en
type
label
Tetracyclines affect prion infectivity.
@ast
Tetracyclines affect prion infectivity.
@en
prefLabel
Tetracyclines affect prion infectivity.
@ast
Tetracyclines affect prion infectivity.
@en
P2093
P2860
P50
P356
P1476
Tetracyclines affect prion infectivity.
@en
P2093
Fabrizio Tagliavini
Giacomina Rossi
Gianluigi Forloni
Giorgio Giaccone
Giorgio Poli
Ilaria Bertani
Laura Colombo
Laura Farina
Laura Girola
Lucia Limido
P2860
P304
10849-10854
P356
10.1073/PNAS.162195499
P407
P577
2002-07-29T00:00:00Z